Morgan Lewis

Related Publications

11/12/12 Court Determines USPTO Is Undercalculating Patent Term Adjustments
District court's decision could lead to a minimum of 17 years of post-issuance patent terms for most standard patents.
12/07/10 Bioequivalence and the "Same Active Ingredient" vis-à-vis Patentability, presented at the Paragraph IV Disputes West conference, San Francisco
05/15/07 Patent and IP Overview for Drugs and Biologics: Hatch-Waxman, Trade Dress, and More, presented at ACI's FDA Boot Camp Basic Training for Products Liability and Patent Lawyers
View all publications

Emerging Business Tools

visit the Entrepreneur Resource Headquarters
Photo of  Robin M. Silva

practice accolades

Patent

Ranked, National Tier 1: Biotechnology Law by U.S. News and Best Lawyers (2010–2012)

bar admissions

  • California

Court Admissions

  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Supreme Court
print profile

Robin M. Silva
Partner


Email: rsilva@morganlewis.com
San Francisco
One Market, Spear Street Tower
San Francisco, CA 94105-1596
Phone: 415.442.1379
Fax: 415.442.1001

Robin M. Silva is a partner in Morgan Lewis's Intellectual Property Practice. Ms. Silva focuses on portfolio strategic development and on management and counseling in domestic and international issues, with an emphasis in emerging biotechnology and biopharmaceutical companies. Her background includes patent prosecution, opinion work (freedom to operate, invalidity, and noninfringement), IP due diligence (financings, evaluating intellectual property portfolios in connection with due diligence for acquisitions, mergers, financings, collaborations, and/or partnering deals), global portfolio management and mining, and working with business development personnel and licensing managers to maximize portfolio value. Ms. Silva has represented a variety of biotechnology clients including universities, start ups, emerging companies, and public companies.  She has 20 years of experience in all aspects of protein chemistry (antibodies and antibody analogs, microbiology and expression systems (bacterial, plant, mammalian)), nucleic acid applications (diagnostics, “lab on a chip,” sequencing, synthesis, RNAi), transgenics (animals, plants), and viruses and vaccines.

Prior to joining Morgan Lewis, Ms. Silva was a partner in the patent group and co-chair of the life sciences group at a large international law firm.

Ms. Silva earned her J.D. from the University of California, Berkeley, Boalt Hall School of Law in 1993. Prior to law school, she worked for six years at Genencor in the protein chemistry department. She earned her B.S. in molecular, cellular, and developmental biology from the University of Colorado in 1984. She is an author on 12 peer-reviewed journal articles.

Ms. Silva is admitted to practice in California and before the U.S. Patent and Trademark Office, the U.S. Court of Appeals for the Federal Circuit, and the U.S. Supreme Court.

education

  • University of California, Berkeley, Boalt Hall School of Law, 1993, J.D.
  • University of Colorado, 1984, B.S. (Molecular, Cellular, and Developmental Biology)